The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Recruiting
CT.gov ID
NCT04953806
Collaborator
(none)
48
1
2
60
0.8

Study Details

Study Description

Brief Summary

Chronic Obstructive Pulmonary Disease (COPD) is prevalent and debilitating chronic disease in Veterans. COPD is highly co-morbid with depression and anxiety conferring greater morbidity and mortality risk. Physical activity is a modifiable behavior that can improve COPD outcomes. However, to date, interventions targeting physical activity have not addressed the high comorbidity between COPD and depression and/or anxiety symptoms ("emotional distress") despite emotional distress predicting poorer response to physical activity interventions. This CDA-2 proposal will develop and test the feasibility and limited-efficacy of an integrative physical activity and mental health intervention for Veterans with COPD, emotional distress, and low physical activity. The intervention will be delivered via VA Video Connect enabling access to care among Veterans with substantial barriers to hospital-based outpatient care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Step-CBT
N/A

Detailed Description

This study will develop and test the feasibility and limited-efficacy of a combined physical activity (PA) and cognitive-behavioral therapy intervention (bCBT) for Veterans with COPD, emotional distress (clinically significant depression and anxiety), and low PA level. Prior research has shown that combined PA+CBT interventions produce superior physical and emotional outcomes in heart failure and diabetes patients. Drawing from this body of literature, the research team will develop and test the feasibility and limited-efficacy of an integrated PA+CBT intervention (Step-CBT) tailored and adapted to COPD patients and delivered via VA Video Connect (VVC). Step-CBT will be an integrated intervention based on established interventions: pedometer-based PA intervention and bCBT. In order to develop Step-CBT, the research team will first conduct mixed-methods interviews with (n=20) Veterans with COPD. Mixed-methods data will identify target behaviors, emotions, and cognitions related to emotional distress and PA, and the research team will integrate this content with existing content included in pedometer-based PA intervention and bCBT. The research team will provide specific language based on patients' lived experience and mirror the language they use to describe their experience. The research team will tailor examples, home exercises, and psychoeducation based on the data collected. The investigators will adapt to delivery over VVC. Step-CBT will then be tested for acceptability with (n=5) Veterans. Acceptability data will be reviewed and submitted to the multidisciplinary expert panel for review and modifications of the treatment protocol will be made based on this process.

Next, Step-CBT will be delivered to Veterans (n=32) compared to enhanced usual care (UC; n = 16) matched for social interaction enrolled through 2:1 randomization for feasibility and limited-efficacy testing with a two week run-in period. Step-CBT will target primary outcomes of step count and patient-reported disability (LLDFI Disability Component), and secondary outcomes of emotional distress (PHQ-9 and BAI). The investigators will measure within-group change in Step-CBT (n=32) and wait-list control (WLC) (n=16) groups from baseline to post-assessment (Week 15). The research team will also compare between-group differences across outcomes. When available, minimally important differences will be used to guide analyses. This study will leverage advances in telehealth interventions. Step-CBT will be deliverable to Veterans' home bypassing numerous barriers to hospital-based care and increasing access to more Veterans with COPD.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Conduct feasibility testing comparing Step-CBT (n=32) to enhanced wait-list control (WLC) (n=16) using 2:1 randomization and two-week run-in period.Conduct feasibility testing comparing Step-CBT (n=32) to enhanced wait-list control (WLC) (n=16) using 2:1 randomization and two-week run-in period.
Masking:
Single (Outcomes Assessor)
Masking Description:
The research assistant will be masked to group assignment and collect all outcome measures.
Primary Purpose:
Treatment
Official Title:
The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity
Actual Study Start Date :
Nov 2, 2021
Anticipated Primary Completion Date :
Nov 1, 2026
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Step-CBT

Participants will complete Step-CBT, an integrative 12-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.

Behavioral: Step-CBT
Participants will complete Step-CBT, an integrative 12-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.

No Intervention: Wait-list control

Participants are assigned to wait-list control

Outcome Measures

Primary Outcome Measures

  1. Measuring change - Late Life Function and Disability Instrument (LLFDI) [Baseline, Week 15 - measuring change]

    Change in scores on the Late Life Function and Disability Instrument (LLFDI) from baseline to Week 15. The LLFDI is a 32-item measure of self-reported functional impairment and disability. Respondents indicate the degree of difficulty they have performing physical activities without the help of someone or using assistive devices. Scores range from 0 to 100 with higher scores indicating higher levels of functioning. We will only use the Disability component of the LLDFI. The LLDFI is sensitive to change and commonly used as an outcome in geriatric research.

  2. Step Count-measuring change [Baseline, Week 6, Week 15- measuring change]

    Change in Step Count. We reference prior MID for estimates of change: Minimally Important Difference = 600-1000 steps. Step count will be measured with the StepWatch Activity Monitor (SAM). The SAM is FDA-approved and highly accurate measure of activity, through the use of a special sensor detecting acceleration, position, and timing, to detect steps. The device is worn around the ankle and unobtrusive. The FitBit Inspire serves as a tool to track step count goals.

Secondary Outcome Measures

  1. Patient Health Questionniare-9- measuring change [Baseline, Week 15- measuring change]

    Change in scores on the Patient Health Questionnaire-9 (PHQ-9) from baseline to Week 15. Meaningful change in the literature is PHQ-9 score (< = 9 combined with improvement of 50%). The PHQ-9 is a 9-item measure of depression symptoms severity mapping on to DSM-IV criteria. Higher scores are indicative of more severe depression symptoms. Score range from 0 to 27, with higher scores indicative of greater depression symptom severity.

  2. Beck Anxiety Inventory- measuring change [Baseline, Week 15- measuring change]

    Change in scores on the Beck Anxiety Inventory (BAI) from baseline to Week 15. Meaningful change in the literature is a 17.5% reduction in BAI scores over time. The BAI is a 21-item screening measure of cognitive and somatic symptoms of anxiety over the past week. Respondents indicate the degree to which they experienced each symptom from 0 (not at all) to 3 (severely), ranging from 0 to 63. Higher scores indicated greater anxiety severity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any gender-identified, greater than or equal to 40 years of age

  • Clinical diagnosis of COPD defined as either the ratio of FEV1 to forced vital capacity < 0.70 or prior documentation of FEV1/FVC ratio of < 0.70 and clinical evidence of COPD (defined as > 10 pack-year cigarette smoking history, dyspnea, or on bronchodilators)

  • PA level below recommended national guidelines for older adults or < 150 minutes of PA per week of moderate intensity based on results of the TAPA

  • Ability to communicate

  • Able to participate in in-session study appointment at the VA

  • Agreeable to audio record study session

  • English speaking

  • Competent to provide informed consent

  • Emotional distress. Clinically significant depression and/or anxiety defined as PHQ-9

10 and/or Beck Anxiety Inventory-II > 13

  • Consent to audio recording of the study session

  • Wireless Internet connection

  • Participants with > 90% accuracy of devices to manual step counts

Exclusion Criteria:
  • COPD exacerbation in the previous 1 month

  • Prescribed supplemental oxygen for activity

  • Chair stand < 16.7 seconds on SPPB

  • Inability to ambulate with or without assistance

  • Use of assistive device for walking such as cane or walker*

  • Inability to complete questionnaires

  • Inability to collect at least 8 days of 14-day baseline step count data.

  • Not currently engaged in psychotherapy.

  • Participation in another exercise-related research study at time of screening

  • Plans to participate in an exercise-related research study in the next 3 months

  • Average baseline step counts of greater than or equal to 10,000 steps per week

Contacts and Locations

Locations

Site City State Country Postal Code
1 VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Boston Massachusetts United States 02130

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Patricia Bamonti, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT04953806
Other Study ID Numbers:
  • D3527-W
First Posted:
Jul 8, 2021
Last Update Posted:
Nov 10, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 10, 2021